## Company Profile

**Industry Sector:** Biotechnology  

**Company Overview:** ECI Biotech, Inc. (ECI) is a premier developer and manufacturer of innovative, patented ExpressDetect® Diagnostics products for rapid infection determination at the point-of-care (PoC) to be used by the healthcare providers as well as consumer OTC markets.

**Target Market(s):** Bioburden Detection for Advanced Wound care  
Approximately 65 mm wounds are treated worldwide annually, of which 14 mm are chronic wounds  

**Other Markets:**  
Yeast Infection (80 mm worldwide)  
Urinary Tract Infection (8.3 mm office visits annually)

## Key Value Drivers

**Technology:** ExpressDetect® simple inexpensive rapid and safe diagnostics  

**Competitive Advantage:** 18 Patents issuing WORLD-WIDE, Fortune 100 Partners  

**Plan & Strategy:**  
ExpressDetect® Point of Care Wound Bioburden Sensor:  
SBIR Phase I funding secured ($200k)  
Diagnostic target selected and threshold of the chemistry set  
Clinical studies indicate excellent sensitivity and specificity profiles  
Phase II SBIR Funding secured ($949k)  
Pre-IDE (Investigational Device Exemption) meeting in preparation  
Suppliers and Partners identified  
Selected for NIH CAP-ACT Program

## Management

**Leadership:**  
Mitchell Sanders, Ph.D.  
Chief Executive Officer and Founder  

Geert Cauwenbergh, Ph.D., Chair of the Advisory Board  

Tara Sharif, Ph.D., MBA  
V.P., Business Development  

**Board of Directors:**  
Mike Landine, Alkermes  
Walter Winshall, Collaborative Seed and Growth Partners  
Dana Edelman, Collaborative Seed and Growth Partners  
Benoit Jamar, Vik Brothers International  
Gustav Vik, Vik Brothers International  
Geert Cauwenbergh, Phase I23  
Mitchell Sanders ECI Biotech

## Product Pipeline

**ExpressDetect® Consumer Strep Diagnostic:**  
Diagnostic targets identified and the threshold of the chemistry set  
Development Partner secured

**ExpressDetect® Yeast Diagnostic:**  
Diagnostic targets identified and the threshold of the chemistry set  
Phase I Grant Funded ($200k)  
Clinical studies underway  
Pre-IDE meeting in preparation  
Suppliers and Partners identified